Jason Broderick

Articles

Olaparib Plus Radium-223 Generates Superior rPFS in CRPC

June 3rd 2025

Olaparib/radium-223 demonstrated superior rPFS outcomes compared with radium-223 alone in patients with castration-resistant prostate cancer.

Patritumab Deruxtecan Does Not Improve Overall Survival in EGFR-Mutated NSCLC

June 1st 2025

Patritumab deruxtecan did not improve OS vs platinum-based chemotherapy in patients with EGFR mutation–positive locally advanced or metastatic NSCLC.

Adjuvant Atezolizumab Plus mFOLFOX6 Improves DFS in dMMR Colon Cancer

June 1st 2025

Adjuvant atezolizumab plus mFOLFOX6 improved disease-free survival vs mFOLFOX6 alone in patients with stage III, mismatch repair–deficient colon cancer.

Invikafusp Alfa Generates Clinical Activity in Checkpoint Inhibitor–Resistant Solid Tumors

April 29th 2025

Invikafusp alfa was active in unresectable, locally advanced or metastatic solid tumors resistant to immune checkpoint inhibitors.

Retrospective Analysis Explores Cabozantinib/Nivolumab vs Lenvatinib/Pembrolizumab in Frontline Advanced RCC

April 28th 2025

A retrospective analysis showed higher response rate for cabozantinib/nivolumab vs. lenvatinib/pembrolizumab in advanced RCC.

Enfortumab Vedotin/Pembrolizumab Elicits Radiographic Responses in Primary UTUC Lesions

February 14th 2025

Enfortumab vedotin, both as monotherapy and in combination with pembrolizumab, demonstrated clinical activity in patients with UTUC lesions.

P-BCMA-ALLO1 Is Safe and Efficacious in R/R Multiple Myeloma

February 14th 2025

P-BCMA-ALLO1 displayed early efficacy and safety data in relapsed/refractory multiple myeloma.

Lutetium Lu 177 Vipivotide Tetraxetan Plus Enzalutamide Boosts OS in mCRPC

February 13th 2025

Adding Lu-PSMA-617 to enzalutamide significantly improved overall survival and quality of life in metastatic castration-resistant prostate cancer.

First-Line Nivolumab/Chemo Generates Long-Term Survival Benefits in Gastric/GEJ/Esophageal Cancer

January 23rd 2025

Frontline nivolumab plus chemotherapy elicited clinically meaningful long-term survival benefits vs chemotherapy alone in advanced gastric/GEJ cancer.

Perioperative Atezolizumab Plus Chemo Does Not Improve EFS in TNBC

December 13th 2024

Treatment with atezolizumab and neoadjuvant chemotherapy followed by adjuvant atezolizumab did not improve EFS in triple-negative breast cancer.

Optimizing Treatment Sequences Remains Key in CLL/SLL

December 12th 2024

Real-world data presented at the 2024 ASH Annual Meeting evaluated the efficacy of the most common treatment sequences in CLL/SLL.

Potential Biomarkers Positively Prognosticate Outcomes With Pembrolizumab Plus Chemo in High-Risk TNBC

December 11th 2024

Pembrolizumab plus chemotherapy conferred an efficacy advantage over chemotherapy alone in high-risk TNBC subgroups defined by potential biomarkers.

Uproleselan Plus Chemo Fails to Produce OS Benefit in Relapsed/Refractory AML

December 9th 2024

The addition of uproleselan to chemotherapy did not meet the primary OS end point of a phase 3 trial evaluating patients with relapsed/refractory AML.

Maintenance Teclistamab With or Without Lenalidomide Is Safe, Active in Newly Diagnosed Myeloma

December 9th 2024

Maintenance therapy with teclistamab with or without lenalidomide was safe and efficacious in newly diagnosed multiple myeloma.

Trastuzumab/Pertuzumab May Be an Effective Chemo-Free Regimen in HR+/HER2+ Breast Cancer

October 2nd 2024

Dual HER2 blockade with trastuzumab plus pertuzumab may serve as an effective option for hormone receptor–positive, HER2-positive metastatic breast cancer.

Cilta-Cel Prolongs OS in Lenalidomide-Refractory Multiple Myeloma

October 1st 2024

Cilta-cel reduced the risk of death by 45% compared with standard of care in patients with multiple myeloma, according to the CARTITUDE-4 study.

Dato-DXd Demonstrates Efficacy, Safety in Platinum-Resistant Ovarian and Endometrial Cancers

September 18th 2024

Datopotamab deruxtecan shows antitumor activity in patients with advanced/metastatic ovarian and endometrial cancer and progressive disease following platinum chemotherapy.

FOLFIRI Plus Encorafenib and Cetuximab Is Active in BRAF V600E–Mutant mCRC

September 15th 2024

Encorafenib, cetuximab, and FOLFIRI demonstrate promising antitumor activity in patients with BRAF V600E-mutant metastatic colorectal cancer.

First-Line T-DXd Combinations Show Early Antitumor Activity in HER2+ Gastric/GEJ Cancers

September 14th 2024

First-line combinations with trastuzumab deruxtecan showed initial efficacy in HER2-positive esophageal, gastric, and gastroesophageal junction cancers.

Analysis Further Shows Perioperative Pembrolizumab Efficacy in Early-Stage NSCLC

September 9th 2024

Neoadjuvant pembrolizumab plus chemotherapy led to greater pathologic regression vs placebo plus chemotherapy in early-stage non–small cell lung cancer.